Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Drug

Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma

Fineline Cube Jul 3, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...

Company Drug

Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 3, 2025

China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...

Company Drug

China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment

Fineline Cube Jul 3, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...

Company Deals

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain

Fineline Cube Jul 3, 2025

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...

Company Drug

AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion

Fineline Cube Jul 3, 2025

US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...

Company Drug

Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis

Fineline Cube Jul 3, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...

Company Deals

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics

Fineline Cube Jul 3, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...

Company Drug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

Fineline Cube Jul 3, 2025

China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...

Company Drug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Fineline Cube Jul 3, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors

Fineline Cube Jul 2, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...

Company Drug

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC

Fineline Cube Jul 2, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...

Company Drug

Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency

Fineline Cube Jul 2, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...

Company Deals

3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions

Fineline Cube Jul 2, 2025

China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences...

Company Drug

Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73

Fineline Cube Jul 2, 2025

China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...

Company Deals Digital

Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation

Fineline Cube Jul 2, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...

Company Drug

Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 2, 2025

China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...

Company Medical Device

China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium

Fineline Cube Jul 2, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...

Company Deals

Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio

Fineline Cube Jul 2, 2025

German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...

Company Drug

Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines

Fineline Cube Jul 2, 2025

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...

Company Deals

Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline

Fineline Cube Jul 2, 2025

This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...

Posts pagination

1 … 101 102 103 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.